Penumbra Inc. (PEN)

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?

PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotec...

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Penumbra Inc PEN stock is trading higher after the company reported better-than-expected first-quarter 2025 earnings and reaffirmed the 2025 forecast.